UNAHUR

Permanent URI for this community

https://repositorio.unahur.edu.ar/handle/123456789/162

Browse

Browsing UNAHUR by Author "Alonso Del Valle, Silvia"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Paclitaxel and curcumin co-loaded mixed micelles. Improving in vitro efficacy and reducing toxicity against Abraxane®
    (2021) Riedel, Jennifer Denise; Bernabeu, Ezequiel Adrián; Calabró López, María Valeria.; Calienni, María Natalia; Lázaro Martínez, Juan Manuel; Prieto, María Jimena; González, Lorena; Martínez, Carolina Soledad; Alonso Del Valle, Silvia; Martinetti Montanari, Jorge Aníbal; Evelson, Pablo Andrés; Chiappetta, Diego Andrés; Moretton, Marcela Analía
    Vismodegib is a first-in-class inhibitor for advanced basal cell carcinoma treatment. Its dailyoral doses present a high distribution volume and several side effects. We evaluated its skin penetration loaded in diverse nanosystems as potential strategies to reduce side effects and drug quantities. Ultradeformable liposomes, ethosomes, colloidal liquid crystals, and dendrimers were able to transport Vismodegib to deep skin layers, while polymeric micelles failed at this. As lipidic systems were the most effective, we assessed the in vitro and in vivo toxicity of Vismodegib-loaded ultradeformable liposomes, apoptosis, and cellular uptake. Vismodegib emerges as a versatile drug that can be loaded in several delivery systems for topical application. These findings may be also useful for the consideration of topical delivery of other drugs with a low water solubility.
  • Thumbnail Image
    Publication
    Vismodegib in PAMAM-dendrimers for potential theragnosis in skin cancer
    (Elsevier, 2022) Ybarra, David Emanuel; Calienni, María Natalia; Ramirez, Luis Felipe Barraza; Aguayo Frias, Eliana Taís; Lillo, Rolando Cristian Rodrigo; Alonso Del Valle, Silvia; Martinetti Montanari, Jorge Aníbal; Alvira, Fernando Carlos
    Vismodegib (VDG) is an antineoplastic, a first-in-class Hedgehog signaling pathway inhibitor, indicated to treat locally advanced or metastatic basal cell carcinoma. Treatment with this drug was approved in 2012 by the US-FDA for oral administration (dose of 150 mg per day) in patients with a refusal of radiotherapy or surgery. However, it presents side effects that influence patient adherence to treatment. Polyamidoamine (PAMAM) dendrimers (D) are promising drug-delivery systems with high water solubility. Additionally, they can penetrate the skin barrier. In this work, we used amine-terminated (DG4.0) and carboxy-terminated (DG4.5) dendrimers of generation 4.0 and 4.5, respectively. We demonstrated that the complexation of VDG with dendrimers (D:VDG complexes) increased its concentration in the aqueous medium. We carried out characterization studies of the complexes to understand how dendrimers interact with VDG, and we found the optimal molar ratios of complexation.